Buradasınız

Anasayfa » Content

BIOSTATISTICAL OPTIMIZATION OF SUSTAINED RELEASE TABLET OF ACYCLOVIR USING LINEAR REGRESSION MODEL AND DETERMINATION OF ITS RELEASE MECHANISM

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2013

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Acyclovir is an antiviral agent which is active in vitro against Herpes simplex (HSV) types I and II and Varicella zoster virus (VZV). Fluctuating biological short half life, low bioavailability, distorted therapeutic drug regimen are some of the characteristics that bestow upon acyclovir to be an ideal Sustained release candidate. The present research paper focuses on designing sustained release tablets of acyclovir to ensure time-dependent, sustained release formulation with optimizing the process variables and perform pre-formulation studies. The results obtain show the linear regression analysis of all the fabricated tablets shown as R2 values . When the data were plotted according to the first-order equation, for all formulations (ACL1 to ACL8) showed a fair linearity, with regression (R2) values between (0.685 - 0.915) clearly indicate that drug was not release as per first order mechanism. These values suggested that more than one mechanism may be involved in release kinetic. In the case of formulation ACL3 with Xanthan gum and sodium alginate shows non-fickian diffusion mechanism with n value as (0.925) therefore diffusion with erosion mechanism play role release from natural gum. So ACL3 was taken as a best formulation to achieve a prolonged maintenance of effective concentrations of drug for a period of 12hrs.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-biostatistical-optimization-sustained-release-tablet-acyclovir-using-linear-regression-model-and-determination-its-release-mechanism.pdf
  • 4
560
567
  • English

REFERENCES

References: 

1) P. Chetoni, S. Rossi, S. Burgalassi, D. Monti, S.
Mariotti, M. F. Saettone. Comparison of liposomeencapsulated
acyclovir with acyclovir ointment:
ocular pharmacokinetics in rabbits, J Ocul
Pharmacol Ther. 20(2): 169-77 (2004).
2) De Clercq, Erik, Field, J. Hugh. Antiviral prodrugs –
the development of successful prodrug strategies
for antiviral chemotherapy, British Journal of
Pharmacology Wiley-Blackwell 147 (1): 1–11
(2006).
3) H. Meulen, P. Nauwynck, P. Deprez, De Backer and S.
B. Garré, K. Shebany, A. Gryspeerdt, K. Baert, K. van
der Croubels, Antimicrob. Agents Chemother,
51(12): 4308 (2007).
4) G. P. Allen, J. T. Bryans. Molecular epizootiology,
pathogenesis and prophylaxis of equine
herpesvirus-1 infections, Prog. Vet. Microbiol.
Immunol. 2: 78–144 (1986).
5) Anonymous. Antiviral agents, In J. E. F. Reynolds
(ed.), Martindale, the Extra Pharmacopoeia, The
Pharmaceutical Press, London, United Kingdom,
1993, 13th ed., pp. 536–563.
6) A. Barger, C. Fuhst, and B. Wiedemann.
Pharmacological indices in antibiotic therapy, J.
Antimicrob. Chemother. 52:893–898 (2003).
7) B. G. Bentz, L. K. Maxwell, R. S. Erkert, C. M. Royer,
M. S. Davis, C. G. MacAllister, and C. R. Clarke.
Pharmacokinetics of acyclovir after single
intravenous and oral administration to adult horses,
J. Vet. Intern. Med. 20: 589–594 (2006).
8) J. T. Bryans, and G. P. Allen. Herpesviral diseases of
the horse, In G. Wittman (ed.), Herpesviral diseases
of cattle, horses and pigs. Kluwer, Boston, MA, 1989,
pp. 176–229.
9) C. Fletcher, and B. Bean. Evaluation of oral acyclovir
therapy. Drug, Intell. Clin. Pharm. 19: 518–524
(1985).
10) K. Yamaoka, T. Nakagawa, and T. Uno. Application of
Akaike’s information criteria (AIC) in the evaluation
of linear pharmacokinetics, J. Pharmacokinet.
Biopharm. 6: 165–175 (1978).
11) S. Tanna, C. Wood, and M. J. Lawrence. Competition
studies to elucidate the mechanisms of acyclovir
uptake in the small intestine, J. Pharm. Pharmacol.
44(Suppl. 1): 1047 (1992).
12)M. Tod, F. Lokiec, R. Bidault, F. De Bony, O. Petitjean,
Y. Aujard, and the Acyclovir Pediatric French Group.
Pharmacokinetics of oral acyclovir in neonate and
infants: a population analysis, Antimicrob. Agents
Chemother. 45:150–157 (2001).
13) G. Stagni, M. E. Ali, D. Weng. Pharmacokinetics of
acyclovir in rabbit skin after i.v.-bolus, ointment,
and iontophoretic administrations, Int. J. Pharm.
274: 201–211 (2004).

Thank you for copying data from http://www.arastirmax.com